Fortress Biotech, Inc. operates a biopharmaceutical business built around acquiring and advancing pharmaceutical and biotechnology assets. Company updates commonly cover product revenue, equity holdings, dividend and royalty income, FDA decisions, subsidiary transactions and clinical or regulatory progress across its portfolio.
Recurring news also includes Journey Medical dermatology products, Cyprium Therapeutics and ZYCUBO® for Menkes disease, priority review voucher monetization and corporate financial results. Fortress reports material developments involving approved prescription products, portfolio-company ownership, royalties, capital resources and business-development activity.
Fortress Biotech (Nasdaq: FBIO) reported third-quarter 2026 revenue of $19.2 million, up approximately 9% from the prior-year quarter. Common stockholders recorded a $7.9 million loss, or $0.23 per basic and diluted share, versus $3.7 million income a year earlier. Consolidated cash reached $152.2 million at September 30, versus $79.4 million at December 31, 2025.
Fortress repaid the remaining $15.0 million Oaktree principal in September, leaving no parent-level debt. A controlled subsidiary licensed FB-607 from Cedars-Sinai for diarrhea-predominant irritable bowel syndrome; Fortress expects Phase 2 top-line data in the second half of 2027. Anselamimab received Japanese approval, while ZYCUBO and UNLOXCYT generated royalties. Nine-month common-stockholder income reached $98.036 million versus $4.316 million, with a $158.873 million net gain on a priority review voucher sale.
Journey Medical (Nasdaq: DERM) reported third-quarter 2026 revenue of $19.0 million, up 8% from the prior-year quarter. Emrosi revenue rose 84% to $9.0 million, with approximately 40,000 total prescriptions. Gross margin increased to 69% from 67%. GAAP net loss narrowed to $1.315 million, or $0.05 per share, from $2.315 million, or $0.09 per share.
Selling, general and administrative expenses rose to $12.593 million from $12.054 million, including a $1.744 million vendor settlement expense. Non-GAAP adjusted EBITDA increased to $3.516 million from $1.389 million. For the first nine months, revenue reached $53.438 million versus $45.779 million, while net loss narrowed to $3.857 million from $10.184 million. Cash fell to $22.323 million at September 30, 2026, from $24.090 million at year-end 2025. Journey expects its expanded sales force and additional health-plan formulary coverage to support further Emrosi adoption.
Fortress Biotech (FBIO) announced that a majority-owned and controlled subsidiary entered an exclusive agreement with Cedars-Sinai to develop FB-607 for IBS-D. The license also enables development for other indications, including hepatic encephalopathy.
FB-607 combines rifaximin and N-acetylcysteine in an enteric-coated, pH-sensitive formulation. It is being evaluated in an ongoing randomized, double-blind, placebo-controlled Phase 2 study for irritable bowel syndrome with diarrhea. The study assesses safety, efficacy and how the drug moves through the body. A proof-of-concept study of rifaximin plus N-acetylcysteine showed efficacy on stool consistency, stool frequency, abdominal pain, bloating and breath testing. In a toxin-induced rat model, the combination normalized measured cytokine levels and reduced elevated E. coli and Desulfovibrio levels.
Journey Medical (DERM) will release its third quarter 2026 financial results after U.S. financial markets close on November 12, 2026. Management will host a conference call and audio webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. A webcast replay will remain available for approximately 30 days after the call.
Journey Medical Corporation (DERM)/b) will participate in two investor conferences in September 2026.Co-Founder, President and CEO Claude Maraoui is scheduled for the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, in New York City in a 1x1 meetings format. He is also scheduled for the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 10:00 a.m. ET, also in New York City, featuring a presentation and 1x1 meetings.
A webcast of the H.C. Wainwright presentation will be available on the News and Events page of the Investors section of Journey Medical’s website for approximately 30 days after the meeting.
Fortress Biotech (FBIO) will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. Chairman, President and CEO Lindsay A. Rosenwald, M.D., is scheduled to deliver the presentation, which will be available for on-demand viewing to conference attendees starting Friday, September 11, 2026, at 7:00 a.m. ET.
Fortress will also participate in one-on-one meetings during the conference, which takes place September 14–16, 2026. The company highlights a portfolio of marketed prescription products and development programs across oncology, dermatology and rare diseases, advanced through majority-owned entities and minority holdings, and supported by partnerships with leading academic and biopharmaceutical organizations.
Fortress Biotech (Nasdaq: FBIO) reported second quarter 2026 net revenue of $18.7 million, up about 14% from $16.4 million a year earlier, driven largely by $17.8 million in dermatology product sales at Journey Medical. Consolidated cash and cash equivalents rose to $196.6 million at June 30, 2026, from $79.4 million at year-end 2025, helped by prior ZYCUBO® priority review voucher monetization.
Research and development expense declined to $0.8 million and selling, general and administrative costs to $20.8 million, down sharply year over year. Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million in the prior-year quarter. Partnered programs advanced, including Crystalys’ $130 million Series B to fund dotinurad Phase 3 development, new royalties from ZYCUBO® and UNLOXCYT™, and AstraZeneca’s subgroup data for anselamimab showing a 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis.
Journey Medical (Nasdaq: DERM) reported second quarter 2026 total revenue of $18.5 million, up 23% from $15.0 million a year earlier, driven by Emrosi® revenue of $8.1 million. Gross margin was 67%, unchanged year over year, and selling, general and administrative expenses declined to $10.9 million, down $1.0 million.
GAAP net loss narrowed to $0.3 million, or $(0.01) per share, versus a $3.8 million loss, or $(0.16) per share, in 2025. Non-GAAP Adjusted EBITDA turned positive at $2.9 million for the quarter. Cash and cash equivalents were $25.6 million at June 30, 2026, compared with $24.1 million at year-end 2025. Emrosi® total prescriptions reached about 36,000 in Q2 2026, versus 30,000 in Q1 2026.
Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.
U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.
Fortress Biotech (Nasdaq: FBIO) and subsidiary Urica Therapeutics reported that Crystalys Therapeutics, in which Urica holds an equity stake, closed an oversubscribed $130 million Series B financing. The capital is intended to fund late-stage global clinical development and commercialization preparation of dotinurad, a once-daily oral URAT1 inhibitor for gout.
Dotinurad’s program includes two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, and the ongoing Phase 2 AMETHYST study across a broad gout population. According to Fortress, the financing is expected to provide Crystalys operational runway through multiple anticipated clinical and regulatory milestones and indirectly benefits Fortress via Urica’s minority equity position in Crystalys and eligibility for a 3% royalty on future net sales of dotinurad.